Zumutor Biologics Secures $7.3 Mn To Advance Clinical Trials For Cancer Therapy
Zumutor Biologics raised $7.3 Mn in Series B funding to advance ZM008 clinical trials, including planned studies in India.
Intelligence analysis by GPT-5.4 Mini
The biotech startup is using the fresh capital to finish its Phase 1 US FDA study, expand into new cohorts, and prepare later-stage trials. The round also signals continued investor interest in Indian biotech and cancer therapeutics.
Zumutor is like a team teaching the body’s own defenders how to spot and fight cancer better. It got new money so it can keep testing its medicine and try bigger studies in India and other places.
Analysis
Funding and trial plans
Zumutor Biologics has raised $7.3 Mn, or about ₹70 Cr, in a Series B round. Existing backers Accel and Bharat Innovation Fund participated again, while Premji Invest joined as a new investor, along with angel investors Ashish Kacholia and Raj Dandu.
The company says the money will help it complete an ongoing US FDA Phase 1 clinical study of ZM008, its cancer drug candidate, both as a single treatment and in combination regimens. It also plans to start Phase 1B expansion cohorts and global Phase 2 studies, including in India.
What Zumutor is building
Founded in 2013 by Kavitha Iyer Rodrigues, Zumutor develops immunotherapy drugs that try to activate the body’s natural immune cells, especially natural killer (NK) cells, so they can attack tumours. The startup describes ZM008 as a first-in-class NK cell checkpoint designed to work against cancer by boosting innate immunity. Human trials with ZM008 began in 2024.
Chief scientific officer Maloy Ghosh said early Phase 1 data show the potential of the therapy for solid tumours and support expansion into dose cohorts and combination studies across multiple tumour types.
Zumutor says it has two proprietary antibody engineering platforms that are used to design immunotherapies aimed at innate immunity and the tumour microenvironment. The company is headquartered in the US and has an R&D lab in Bengaluru.
Broader context
The round lands as the Indian government pushes harder on biotech. Inc42 notes Finance Minister Nirmala Sitharaman announced a new Biopharma SHAKTI scheme with a ₹10,000 Cr outlay, plus support through single-window clearance and the BIRAC SEED scheme. The article also points to other recent biotech fundraises, suggesting investor interest is broadening across the sector.
Key points
- Zumutor Biologics raised $7.3 Mn in a Series B round from existing and new investors.
- The company plans to use the funds to complete its US FDA Phase 1 study of ZM008.
- It will also start Phase 1B expansion cohorts and global Phase 2 studies, including in India.
- Zumutor focuses on immunotherapy that activates natural killer cells to fight cancer.
- The fundraise comes amid government support for India’s biotech sector.
If the Phase 1 data continue to look promising, Zumutor could move into larger expansion cohorts and Phase 2 studies with stronger confidence. Success there would strengthen its case for a first-in-class cancer therapy and could validate its antibody platforms.
The drug is still early in testing, so later stages could fail even if initial data look encouraging. The company also has to navigate long clinical timelines and regulatory complexity before any broader commercial outcome is possible.
